Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Publication year range
1.
Ann Hepatol ; 17(3): 403-412, 2018.
Article in English | MEDLINE | ID: mdl-29735790

ABSTRACT

INTRODUCTION AND AIM: Multiple prognostic scores are available for acute liver failure (ALF). Our objective was to compare the dynamicity of model for end stage liver disease (MELD), MELD-sodium, acute liver failure early dynamic model (ALFED), chronic liver failure (CLIF)-consortium ACLF score and King's College Hospital Criteria (KCH) for predicting outcome in ALF. MATERIALS AND METHODS: All consecutive patients with ALF at a tertiary care centre in India were included. MELD, MELD-Na, ALFED, CLIF-C ACLF scores and KCH criteria were calculated at admission and day 3 of admission. Area under receiver operator characteristic curves (AUROC) were compared with DeLong method. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), likelihood ratio (LR) and diagnostic accuracy (DA) were reported. RESULTS: Of the 115 patients included in the study, 73 (63.5%) died. The discrimination of mortality with baseline values of prognostic scores (MELD, MELD-Na, ALFED, CLIF-C ACLF and KCH) was modest (AUROC: 0.65-0.77). The AUROC increased on day 3 for all scores, except KCH criteria. On day 3 of admission, ALFED score had the highest AUROC 0.95, followed by CLIF-C ACLF 0.88, MELD 0.81, MELD-Na 0.77 and KCH 0.52. The AUROC for ALFED was significantly higher than MELD, MELD-Na and KCH (P < 0.001 for all) and CLIF-C ACLF (P = 0.05). ALFED score ≥ 4 on day 3 had the best sensitivity (87.1%), specificity (89.5%), PPV (93.8%), NPV (79.1%), LR positive (8.3) and DA (87.9%) for predicting mortality. CONCLUSIONS: Dynamic assessment of prognostic scores better predicts outcome. ALFED model performs better than MELD, MELD, MELD-Na, CLIF-C ACLF scores and KCH criteria for predicting outcome in viral hepatitis- related ALF.


Subject(s)
Decision Support Techniques , Hepatitis B/diagnosis , Hepatitis E/diagnosis , Liver Failure, Acute/diagnosis , Adult , Disease Progression , Female , Hepatitis B/mortality , Hepatitis B/therapy , Hepatitis B/virology , Hepatitis E/mortality , Hepatitis E/therapy , Hepatitis E/virology , Hospital Mortality , Humans , India , Liver Failure, Acute/mortality , Liver Failure, Acute/therapy , Liver Failure, Acute/virology , Male , Patient Admission , Predictive Value of Tests , Prognosis , Prospective Studies , Reproducibility of Results , Risk Assessment , Risk Factors , Time Factors , Young Adult
2.
Sante ; 16(4): 239-43, 2006.
Article in French | MEDLINE | ID: mdl-17446156

ABSTRACT

Hepatitis E virus (HEV) is a spherical, non-enveloped, single stranded RNA virus. Four genotypes (1-4) have so far been distinguished. HEV infection can occur either in large epidemics (in endemic regions only: southeast Asia, India, central Asia central, Africa, and Mexico) or in sporadic forms. HEV is transmitted principally by the fecal-oral pathway, that is, hand-to-mouth. There is a risk of transmission from animals to humans. Nearly half of all cases have no or few symptoms. Symptomatic forms can be severe. The mortality rate can reach 20% in pregnant women. Recent reports indicate that autochthonous cases have been contracted in France. Several aspects differentiate sporadic autochthonous hepatitis from that contracted in endemic areas: 1) mean age of onset is older in the former; 2) prognosis is more severe; and 3) prolonged even chronic forms can affect some immunocompromised patients, in particular, those with organ transplants. The diagnosis of hepatitis E must now be considered in any cases of acute hepatitis of unexplained origin in France. Diagnosis relies on RT-PCR testing of blood or stool.


Subject(s)
Communicable Diseases, Emerging/epidemiology , Hepatitis E/epidemiology , Adult , Africa/epidemiology , Age Factors , Animals , Asia/epidemiology , Child , Disease Outbreaks , Endemic Diseases , France/epidemiology , Hepatitis E/mortality , Hepatitis E/transmission , Hepatitis E virus/classification , Humans , Immunocompromised Host , Mexico/epidemiology , Organ Transplantation , Prognosis , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , Zoonoses
3.
J Pediatr ; 131(4): 536-40, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9386654

ABSTRACT

OBJECTIVES: To delineate the importance of non-A, non-B, non-C (non-ABC) hepatitis, and the role of GB virus C (GBV-C) in children. METHODS: From 1980 to 1995, acute-onset viral hepatitis was diagnosed in 166 inpatients and categorized into type A, B, C, and non-ABC hepatitis according to the serologic markers or the results of polymerase chain reaction assay for HBV DNA or HCV ribonucleic acid (RNA) in the National Taiwan University Hospital. Non-ABC hepatitis was diagnosed in 57 patients (34%). GBV-C RNA was investigated by reverse transcription and nested polymerase chain reaction in 32 of the 57 patients with non-ABC hepatitis. The clinical and laboratory features of patients with acute non-ABC hepatitis were compared with the features of those with acute hepatitis A and B. RESULTS: The degree of abnormality in aminotransferase activities was milder in patients with non-ABC hepatitis than in those with hepatitis B; chronicity was noted in 12%. Fulminant hepatitis occurred in 16%, and the mortality rate was 56%. Young age carried a significantly higher risk of having a fulminant course (1.9 +/- 0.2 years of age vs 6.4 +/- 5.1 years of age in acute course; p < 0.05). Compared with fulminant hepatitis B, fulminant non-ABC hepatitis had a trend of a longer interval from onset to death (119.2 +/- 144.8 vs 15.2 +/- 8.4 days; p = 0.079). GBV-C RNA was detected in only two of the patients tested, both of whom had received transfusions; one had persistent viremia and fluctuating aminotransferase values. CONCLUSIONS: Non-ABC hepatitis plays an important role in the etiology of pediatric viral hepatitis; however, the role of GBV-C is minor. A search for other unknown viral agent(s) responsible for non-ABCG hepatitis is needed.


Subject(s)
Flaviviridae , Hepatitis C/virology , Hepatitis E/virology , Acute Disease , Child, Preschool , Chronic Disease , DNA, Viral/analysis , Female , Flaviviridae/genetics , Hepatitis C/enzymology , Hepatitis C/mortality , Hepatitis E/enzymology , Hepatitis E/mortality , Humans , Liver/enzymology , Liver Function Tests , Male , RNA, Viral/analysis , Retrospective Studies , Survival Rate , Transaminases/metabolism
4.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);73(6): 367-76, nov.-dez. 1997. ilus, tab
Article in Portuguese | LILACS | ID: lil-211797

ABSTRACT

Objetivo: os autores apresentaram uma revisäo dos diferentes tipos de hepatite viral na infância. Säo discutidos, com ênfase especial, os aspectos clínicos-laboratoriais e evolutivos das formas mais freqüentes da doença. Métodos: Foram selecionados, através de Medline, os artigos mais significativos publicados nos últimos anos sobre hepatite viral na infância. As características epidemiológicas säo discutidas, sempre que possível, levando em conta dados brasileiros. Resultados: A presente revisäo analisa as hepatites causadas por agentes que têm em comum a origem viral e o hepatotropismo mas que determinam doenças com diferenças marcantes sobretudo quanto a evoluçäo e prognóstico. Em relaçäo ao vírus B, por exemplo o paciente pode apresentar desde um simples estado de portador até hepatite aguda, hepatite crônica, cirrose...


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Adult , Flaviviridae , Hepatitis A , Hepatitis A/diagnosis , Hepatitis A/therapy , Hepatitis B , Hepatitis B/diagnosis , Hepatitis B/therapy , Hepatitis D , Hepatitis D/diagnosis , Hepatitis D/transmission , Hepatitis E , Hepatitis E/mortality , Hepatitis E/transmission , Hepatitis, Viral, Human , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/etiology , Hepatitis Antigens , Immunologic Tests , Vaccines
SELECTION OF CITATIONS
SEARCH DETAIL